A Phase 2a, multi-center, single-blind, within-subject, placebo-controlled study to assess the pharmacodynamics of ACT-709478 in subjects with photosensitive epilepsy
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs ACT 709478 (Primary)
- Indications Reflex epilepsy
- Focus Pharmacodynamics
- Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals
- 25 Jul 2018 Status changed from recruiting to completed.
- 07 Nov 2017 Status changed from not yet recruiting to recruiting.
- 25 Oct 2017 Planned initiation date changed from 9 Oct 2017 to 14 Nov 2017.